Semantic Scholar uses AI to extract papers important to this topic.
Early and late vascular obstruction are both related to platelet adhesion and aggregation in the grafts. We assessed… Expand Satigrel (E5510, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid) is a potent inhibitor of platelet aggregation. Like… Expand OBJECTIVE
Satigrel is a new antiplatelet agent which was previously shown to inhibit platelet aggregation and have an anti… Expand A novel antiplatelet agent, satigrel (E5510), was administered to 9 patients with arteriosclerosis obliterans (ASO) and 6… Expand E5510, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid, is a new anti-platelet-aggregation agent under development. We examined… Expand The mode of action of E5510, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid, which has very potent anti-platelet activities… Expand Non-heparin hemodialysis (HD) was successfully done in anuric dogs with the oral administration of a newly developed antiplatelet… Expand Various pharmacological properties of a new antiplatelet aggregating agent, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid (E… Expand